Evidence map›Paper›PMID 35941977›Full record

ReviewBioMed research international2022

Big Data Analysis of Manufacturing and Preclinical Studies of Nanodrug-Targeted Delivery Systems: A Literature Review.

Qiang Cao, Xiaochen Li, Qi Zhang, Kexuan Zhou, Ying Yu, Zixu He, Zhibiao Xiang, Yi Qiang, Wei Qi

RetractedOpen access · hybridAbstract readReviewRetracted Publication
In one paragraph

Review in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 3 countries.

Qiang CaoSchool of Pharmacy, Macau University of Science and Technology, China.ORCID https://orcid.org/0000-0001-8160-8883
Xiaochen LiThe Third Affiliated Hospital of Shandong First Medical University, China.ORCID https://orcid.org/0000-0002-5281-0633
Qi ZhangTaishan University, China.ORCID https://orcid.org/0000-0003-4078-6346
Kexuan ZhouHainan University, China.ORCID https://orcid.org/0000-0002-9005-3047
Ying YuTaishan University, China.ORCID https://orcid.org/0000-0002-4051-1580
Zixu HeUniversity of New South Wales, University of New South Wales, Australia.ORCID https://orcid.org/0000-0002-1742-3937
Zhibiao XiangSecond Xiangya Hospital, The Second Xiangya Hospital, China.ORCID https://orcid.org/0000-0002-4783-1536
Yi QiangKunming University of Science and Technology, China.ORCID https://orcid.org/0000-0002-9557-2268
Wei QiSchool of Pharmacy, Macau University of Science and Technology, China.ORCID https://orcid.org/0000-0002-4252-2953
Macau University of Science and Technology · MOTaishan University · CNCentral South University · CNHainan University · CNKunming University of Science and Technology · CNShandong First Medical University · CNUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Nanodelivery is a modern technology involving improved delivery methods and drug formulations. The current development and initial applications of nanocarriers are pointing to new directions in the current development of nanomedicine. Researchers are increasingly applying nanodelivery to the delivery of therapeutic or diagnostic agents. This article discusses the preparation and application of nanocomplexes and nanoparticles, as well as their potential future value in clinical research. Through a review and analysis, it is hoped that this will serve as a guide for the future development of various nanodelivery technologies and help researchers learn more about these technologies. Materials and Methods: A literature search was conducted using the keywords "Nano drug delivery" or "Nanomedical materials" or "Nano". A literature search was conducted in three major databases, PubMed, Web of Science, and Google Scholar, using the keywords such as "Nano drug delivery", "Nanomedical materials", or "Nanobubble drug delivery". The initial search was screened by title and abstract. In the full-text review, the titles or abstracts were reviewed according to the selection criteria based on the inclusion criteria. The risk of bias and study quality was assessed according to the Cochrane guidelines, and possible biases such as selection bias and good selection bias were included in the review. Results: A total of 297 studies were included in this study, of which 219 were excluded based on the screening criteria, resulting in the inclusion of 78 studies, the majority of which were original studies and clinical trials, and a small number of which provided design and route of administration analysis of nanomaterial particles and effect fluorograms and were studied in more depth. This paper summarises and reviews the views and directions of the included articles. The main directions include cyclodextrin-based or grafted cyclodextrin nanomaterials, nanobubbles, and stimuli-sensitive and temperature-sensitive nanodelivery systems. Conclusion: The use of innovative, targeted drug delivery systems is effective in cancer drug delivery by summarising the previous studies. However, nanodelivery systems' risks and therapeutic effects need to be evaluated before clinical application. Future research in the field of targeted drug delivery nanosystems should focus on the development of nanocarriers with high in vivo delivery capacity, good synergy with therapeutic agents, and milder short-term and long-term toxicological effects and conduct comprehensive preclinical trials on nanodrug delivery systems with high potential for clinical application as soon as possible, to find nanodrug delivery systems suitable for clinical use and put them into the clinical application as soon as possible.

Indexed as

CyclodextrinsNanoparticlesData AnalysisDrug Delivery SystemsNanomedicineCyclodextrins

Identifiers

PMID35941977
PMCPMC9356884
OpenAlexW4288902561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.